{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Multi-Cancer+Cancer+Panel&page=9", "query": { "intervention": "Multi-Cancer Cancer Panel", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 344, "total_pages": 35, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Multi-Cancer+Cancer+Panel&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Multi-Cancer+Cancer+Panel&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T10:17:16.518Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00379470", "title": "Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Glioblastoma Multiforme" ], "interventions": [ { "name": "NovoTTF-100A", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "NovoCure Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 236, "start_date": "2006-09", "completion_date": "2011-01", "has_results": false, "last_update_posted_date": "2012-05-01", "last_synced_at": "2026-10-21T10:17:16.518Z", "location_count": 15, "location_summary": "Chicago, Illinois • Evanston, Illinois • Boston, Massachusetts + 7 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00379470" }, { "nct_id": "NCT02466061", "title": "TREC Lifestyle Beyond Cancer Study in Endometrial Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "Telemedicine Weight Management plus Wi-Fi Scale (Arm A)", "type": "BEHAVIORAL" }, { "name": "Text for Diet (Text4Diet) Group (Arm B)", "type": "BEHAVIORAL" }, { "name": "Enhanced Usual Care Group (Arm C)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 207, "start_date": "2014-07", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2016-06-02", "last_synced_at": "2026-10-21T10:17:16.518Z", "location_count": 3, "location_summary": "Boston, Massachusetts • St Louis, Missouri • Philadelphia, Pennsylvania", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02466061" }, { "nct_id": "NCT07005154", "title": "A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer", "Metastatic Castration-Resistant Prostate Cancer", "Metastatic Hormone Sensitive Prostate Cancer" ], "interventions": [ { "name": "ASP5541", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "abiraterone acetate", "type": "DRUG" }, { "name": "Adrenocorticotropic hormone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 218, "start_date": "2025-08-19", "completion_date": "2032-05-31", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-21T10:17:16.518Z", "location_count": 12, "location_summary": "Huntsville, Alabama • San Diego, California • Tampa, Florida + 9 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago Ridge", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07005154" }, { "nct_id": "NCT01815359", "title": "ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Appendix Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "Cytoreductive Surgery", "type": "PROCEDURE" }, { "name": "HIPEC with Mitomycin-C", "type": "DRUG" }, { "name": "EPIC with FUDR and Leucovorin", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 292, "start_date": "2013-03", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-21T10:17:16.518Z", "location_count": 9, "location_summary": "Miami, Florida • St Louis, Missouri • Basking Ridge, New Jersey + 6 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01815359" }, { "nct_id": "NCT07352579", "title": "From Screening to Support: A Multi-Method Analysis of HRSN Integration in Cancer Care", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer" ], "interventions": [ { "name": "Survey", "type": "OTHER" }, { "name": "Interview", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2025-12-11", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-10-21T10:17:16.518Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07352579" }, { "nct_id": "NCT02892123", "title": "Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-expressing Cancers" ], "interventions": [ { "name": "ZW25 (Zanidatamab)", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Tucatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 279, "start_date": "2016-09-30", "completion_date": "2024-10-31", "has_results": false, "last_update_posted_date": "2024-11-27", "last_synced_at": "2026-10-21T10:17:16.518Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02892123" }, { "nct_id": "NCT02648724", "title": "Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Oncology", "MET Gene Amplification", "NSCLC", "MET Gene Mutation", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Sym015", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Symphogen A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2016-03", "completion_date": "2020-12", "has_results": true, "last_update_posted_date": "2022-06-22", "last_synced_at": "2026-10-21T10:17:16.518Z", "location_count": 10, "location_summary": "Aurora, Colorado • Chicago, Illinois • Indianapolis, Indiana + 6 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02648724" }, { "nct_id": "NCT02287766", "title": "Metabolic Syndrome Feasibility Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metabolic Syndrome" ], "interventions": [], "intervention_types": [], "sponsor": "Epic Research & Diagnostics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "21 Years to 85 Years" }, "enrollment_count": 193, "start_date": "2014-11", "completion_date": "2015-08", "has_results": false, "last_update_posted_date": "2015-08-04", "last_synced_at": "2026-10-21T10:17:16.518Z", "location_count": 2, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02287766" }, { "nct_id": "NCT03285490", "title": "A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Actinic Keratosis" ], "interventions": [ { "name": "KX2-391 Ointment 1%", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Almirall, S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 351, "start_date": "2017-09-15", "completion_date": "2019-04-24", "has_results": true, "last_update_posted_date": "2021-03-10", "last_synced_at": "2026-10-21T10:17:16.518Z", "location_count": 30, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 27 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Murrieta", "state": "California" }, { "city": "Oceanside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03285490" }, { "nct_id": "NCT01379534", "title": "A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors and Advanced Endometrial Cancer", "Endometrial Cancer", "Second-line Treatment", "VEGF" ], "interventions": [ { "name": "TKI258", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 53, "start_date": "2011-11", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2015-05-20", "last_synced_at": "2026-10-21T10:17:16.518Z", "location_count": 21, "location_summary": "Mobile, Alabama • Fullerton, California • Los Angeles, California + 15 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01379534" } ] }